The findings were presented by Dr. Wungki Park of Memorial Sloan Kettering Cancer Center in New York City at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The study involved 61 patients with metastatic PDAC who received daraxonrasib along with gemcitabine and nab-paclitaxel, a standard chemotherapy regimen. The primary endpoint was the confirmed objective response rate (ORR), which measures the proportion of patients whose tumors shrank by a defined amount or disappeared entirely.
The results indicated that 61% of the patients achieved an objective response. This included a complete response—where tumors became undetectable—in 8.2% of the participants. The median duration of this response was 11.1 months. Furthermore, the median progression-free survival (PFS), which is the time until the disease worsens or the patient dies, was 12.8 months, with a 12-month PFS rate of 51.7%. The most striking statistic was the overall survival (OS) rate at 12 months, which stood at 76.6%.

These figures compare favorably to historical benchmarks for conventional chemotherapy alone. Dr. Park noted that the observed survival rates are already outpacing the high end of the historical overall survival range of 8.5 to 11.1 months typically seen with standard treatments. Other reports suggest that more than three-quarters of patients in trials using daraxonrasib survived past 12 months, compared to approximately 25% using standard chemotherapy alone. This substantial difference in survival rates has led some experts to describe the drug as a “game-changing” development and the “biggest breakthrough in decades” for a disease that has historically seen limited progress.
Dr. Shivan Sivakumar, a PhD from the University of Birmingham in England, commented on the findings via the Science Media Centre website, calling them “very encouraging.” He highlighted the potential to move beyond chemotherapy by targeting RAS, a mutation present in most pancreatic cancers. “By targeting RAS, a fundamental driver of the vast majority of pancreatic cancers, we may be entering an era where molecularly targeted therapies can meaningfully improve outcomes for patients,” Dr. Sivakumar said.
However, medical experts emphasize that these results must be interpreted with caution. The reported data comes from an early-stage trial with a relatively small sample size of 61 patients. Crucially, the study did not include a randomized control group, meaning it is not yet possible to definitively attribute the improved survival solely to the addition of daraxonrasib without the confounding variables of patient selection and the lack of a direct comparison arm within the same trial. Dr. Sivakumar cautioned that the findings should be viewed as preliminary.

Daraxonrasib is described as a first-in-class oral RAS(ON) multi-selective inhibitor. Unlike previous approaches that focused on specific mutations, this drug targets both mutant and wild-type RAS proteins in their active, GTP-bound state. In patients with previously treated metastatic disease, the drug has been noted to double overall survival and progression-free survival compared to historical controls, though the current data focuses on its use as a first-line treatment alongside chemotherapy.
The next critical step in validating these findings is the phase III RASolute 303 trial. If the results from this larger, randomized study confirm the early-stage data, Dr. Sivakumar suggested it could represent one of the most significant advances in the first-line treatment of metastatic pancreatic cancer in recent years. Until such data is available, the drug remains an experimental therapy, and the current results, while highly encouraging, do not yet constitute a cure or a standard of care. The medical community awaits these regulatory and clinical milestones to determine if daraxonrasib will indeed transform the landscape of pancreatic cancer management.



